ID   SYNJ1_HUMAN             Reviewed;        1573 AA.
AC   O43426; O43425; O94984; Q4KMR1;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   10-MAY-2017, entry version 170.
DE   RecName: Full=Synaptojanin-1;
DE            EC=3.1.3.36;
DE   AltName: Full=Synaptic inositol 1,4,5-trisphosphate 5-phosphatase 1;
GN   Name=SYNJ1; Synonyms=KIAA0910;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND VARIANT ARG-295.
RC   TISSUE=Cerebellum;
RX   PubMed=9428629; DOI=10.1016/S0014-5793(97)01451-8;
RA   Haffner C., Takei K., Chen H., Ringstad N., Hudson A., Butler M.H.,
RA   Salcini A.E., Di Fiore P.P., De Camilli P.;
RT   "Synaptojanin 1: localization on coated endocytic intermediates in
RT   nerve terminals and interaction of its 170 kDa isoform with Eps15.";
RL   FEBS Lett. 419:175-180(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=10048485; DOI=10.1093/dnares/5.6.355;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M.,
RA   Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XII.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 5:355-364(1998).
RN   [3]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
RA   Park H.-S., Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y.,
RA   Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K.,
RA   Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
RA   Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
RA   Rosenthal A., Kudoh J., Shibuya K., Kawasaki K., Asakawa S.,
RA   Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,
RA   Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brandt P.,
RA   Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Bloecker H.,
RA   Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E.,
RA   Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F.,
RA   Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH AMPH; SH3GL1; SH3GL2 AND SH3GL3.
RX   PubMed=10542231; DOI=10.1074/jbc.274.45.32001;
RA   Cestra G., Castagnoli L., Dente L., Minenkova O., Petrelli A.,
RA   Migone N., Hoffmueller U., Schneider-Mergener J., Cesareni G.;
RT   "The SH3 domains of endophilin and amphiphysin bind to the proline-
RT   rich region of synaptojanin 1 at distinct sites that display an
RT   unconventional binding specificity.";
RL   J. Biol. Chem. 274:32001-32007(1999).
RN   [7]
RP   INTERACTION WITH MYO1E.
RX   PubMed=17257598; DOI=10.1016/j.febslet.2007.01.021;
RA   Krendel M., Osterweil E.K., Mooseker M.S.;
RT   "Myosin 1E interacts with synaptojanin-1 and dynamin and is involved
RT   in endocytosis.";
RL   FEBS Lett. 581:644-650(2007).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-830; THR-1220; SER-1551
RP   AND SER-1565, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-830, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1318, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-830; THR-1220; SER-1292;
RP   SER-1345 AND SER-1565, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1220, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   STRUCTURE BY NMR OF 894-971.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of RNA binding domain in synaptojanin 1.";
RL   Submitted (OCT-2006) to the PDB data bank.
RN   [14]
RP   VARIANT PARK20 GLN-219, AND CHARACTERIZATION OF VARIANT PARK20
RP   GLN-219.
RX   PubMed=23804563; DOI=10.1002/humu.22372;
RA   Krebs C.E., Karkheiran S., Powell J.C., Cao M., Makarov V.,
RA   Darvish H., Di Paolo G., Walker R.H., Shahidi G.A., Buxbaum J.D.,
RA   De Camilli P., Yue Z., Paisan-Ruiz C.;
RT   "The Sac1 domain of SYNJ1 identified mutated in a family with early-
RT   onset progressive Parkinsonism with generalized seizures.";
RL   Hum. Mutat. 34:1200-1207(2013).
RN   [15]
RP   VARIANTS PARK20 GLN-219 AND ARG-1383.
RX   PubMed=23804577; DOI=10.1002/humu.22373;
RA   Quadri M., Fang M., Picillo M., Olgiati S., Breedveld G.J.,
RA   Graafland J., Wu B., Xu F., Erro R., Amboni M., Pappata S.,
RA   Quarantelli M., Annesi G., Quattrone A., Chien H.F., Barbosa E.R.,
RA   Oostra B.A., Barone P., Wang J., Bonifati V.;
RT   "Mutation in the SYNJ1 gene associated with autosomal recessive,
RT   early-onset Parkinsonism.";
RL   Hum. Mutat. 34:1208-1215(2013).
CC   -!- FUNCTION: Inositol 5-phosphatase which has a role in clathrin-
CC       mediated endocytosis.
CC   -!- CATALYTIC ACTIVITY: 1-phosphatidyl-1D-myo-inositol 4,5-
CC       bisphosphate + H(2)O = 1-phosphatidyl-1D-myo-inositol 4-phosphate
CC       + phosphate.
CC   -!- SUBUNIT: Interacts with ASH/GRB2. Interacts with PACSIN1, PACSIN2
CC       and PACSIN3 (By similarity). Binds AMPH, SH3GL1, SH3GL2 and
CC       SH3GL3. Interacts with MYO1E (via SH3 domain). {ECO:0000250,
CC       ECO:0000269|PubMed:10542231, ECO:0000269|PubMed:17257598}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Synaptojanin-170;
CC         IsoId=O43426-1; Sequence=Displayed;
CC       Name=2; Synonyms=Synaptojanin-145;
CC         IsoId=O43426-2; Sequence=VSP_002682, VSP_002683;
CC       Name=3;
CC         IsoId=O43426-4; Sequence=VSP_041578, VSP_002682, VSP_002683;
CC       Name=4;
CC         IsoId=O43426-5; Sequence=VSP_035709, VSP_035710, VSP_035711;
CC   -!- TISSUE SPECIFICITY: Concentrated at clathrin-coated endocytic
CC       intermediates in nerve terminals. Isoform 1 is more enriched than
CC       isoform 2 in developing brain as well as non-neuronal cells.
CC       Isoform 2 is very abundant in nerve terminals.
CC   -!- DOMAIN: Binds to EPS15 (a clathrin coat-associated protein) via a
CC       C-terminal domain containing three Asn-Pro-Phe (NPF) repeats.
CC       {ECO:0000250}.
CC   -!- DOMAIN: The C-terminal proline-rich region mediates binding to a
CC       variety of SH3 domain-containing proteins including AMPH, SH3GL1,
CC       SH3GL2, SH3GL3 and GRB2.
CC   -!- DISEASE: Parkinson disease 20, early-onset (PARK20) [MIM:615530]:
CC       An early-onset form of Parkinson disease, a complex
CC       neurodegenerative disorder characterized by bradykinesia, resting
CC       tremor, muscular rigidity and postural instability, as well as by
CC       a clinically significant response to treatment with levodopa. The
CC       pathology involves the loss of dopaminergic neurons in the
CC       substantia nigra and the presence of Lewy bodies (intraneuronal
CC       accumulations of aggregated proteins), in surviving neurons in
CC       various areas of the brain. PARK20 is characterized by young
CC       adult-onset of parkinsonism. Additional features may include
CC       seizures, cognitive decline, abnormal eye movements, and dystonia.
CC       {ECO:0000269|PubMed:23804563, ECO:0000269|PubMed:23804577}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the synaptojanin family. {ECO:0000305}.
CC   -!- SIMILARITY: In the central section; belongs to the inositol 1,4,5-
CC       trisphosphate 5-phosphatase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA74933.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF009039; AAC51921.1; -; mRNA.
DR   EMBL; AF009040; AAC51922.1; -; mRNA.
DR   EMBL; AB020717; BAA74933.2; ALT_INIT; mRNA.
DR   EMBL; AP000275; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000276; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000277; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000278; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000279; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC098395; AAH98395.1; -; mRNA.
DR   CCDS; CCDS54483.1; -. [O43426-4]
DR   RefSeq; NP_001153774.1; NM_001160302.1. [O43426-4]
DR   RefSeq; NP_001153778.1; NM_001160306.1.
DR   RefSeq; NP_003886.3; NM_003895.3.
DR   RefSeq; NP_982271.2; NM_203446.2.
DR   RefSeq; XP_016883989.1; XM_017028500.1. [O43426-2]
DR   UniGene; Hs.473632; -.
DR   PDB; 1W80; X-ray; 1.90 A; P=1477-1488, Q=1458-1469.
DR   PDB; 2DNR; NMR; -; A=894-971.
DR   PDB; 2VJ0; X-ray; 1.60 A; P=1477-1488.
DR   PDBsum; 1W80; -.
DR   PDBsum; 2DNR; -.
DR   PDBsum; 2VJ0; -.
DR   ProteinModelPortal; O43426; -.
DR   SMR; O43426; -.
DR   BioGrid; 114388; 16.
DR   IntAct; O43426; 6.
DR   MINT; MINT-109209; -.
DR   STRING; 9606.ENSP00000409667; -.
DR   DEPOD; O43426; -.
DR   iPTMnet; O43426; -.
DR   PhosphoSitePlus; O43426; -.
DR   BioMuta; SYNJ1; -.
DR   EPD; O43426; -.
DR   MaxQB; O43426; -.
DR   PaxDb; O43426; -.
DR   PeptideAtlas; O43426; -.
DR   PRIDE; O43426; -.
DR   Ensembl; ENST00000357345; ENSP00000349903; ENSG00000159082. [O43426-4]
DR   GeneID; 8867; -.
DR   KEGG; hsa:8867; -.
DR   UCSC; uc002yqf.2; human. [O43426-1]
DR   CTD; 8867; -.
DR   DisGeNET; 8867; -.
DR   GeneCards; SYNJ1; -.
DR   HGNC; HGNC:11503; SYNJ1.
DR   HPA; HPA011916; -.
DR   MalaCards; SYNJ1; -.
DR   MIM; 604297; gene.
DR   MIM; 615530; phenotype.
DR   neXtProt; NX_O43426; -.
DR   OpenTargets; ENSG00000159082; -.
DR   Orphanet; 391411; Atypical juvenile parkinsonism.
DR   PharmGKB; PA36285; -.
DR   eggNOG; KOG0566; Eukaryota.
DR   eggNOG; COG5329; LUCA.
DR   eggNOG; COG5411; LUCA.
DR   GeneTree; ENSGT00760000119075; -.
DR   HOGENOM; HOG000007937; -.
DR   HOVERGEN; HBG079225; -.
DR   InParanoid; O43426; -.
DR   KO; K20279; -.
DR   PhylomeDB; O43426; -.
DR   BioCyc; MetaCyc:HS08354-MONOMER; -.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-1855183; Synthesis of IP2, IP, and Ins in the cytosol.
DR   Reactome; R-HSA-1855204; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   SIGNOR; O43426; -.
DR   ChiTaRS; SYNJ1; human.
DR   EvolutionaryTrace; O43426; -.
DR   GenomeRNAi; 8867; -.
DR   PRO; PR:O43426; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   Bgee; ENSG00000159082; -.
DR   CleanEx; HS_SYNJ1; -.
DR   ExpressionAtlas; O43426; baseline and differential.
DR   Genevisible; O43426; HS.
DR   GO; GO:0030132; C:clathrin coat of coated pit; ISS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0030117; C:membrane coat; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0098793; C:presynapse; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0097060; C:synaptic membrane; ISS:BHF-UCL.
DR   GO; GO:0043195; C:terminal bouton; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0012506; C:vesicle membrane; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0052659; F:inositol-1,3,4,5-tetrakisphosphate 5-phosphatase activity; TAS:Reactome.
DR   GO; GO:0052658; F:inositol-1,4,5-trisphosphate 5-phosphatase activity; TAS:Reactome.
DR   GO; GO:0034596; F:phosphatidylinositol phosphate 4-phosphatase activity; TAS:Reactome.
DR   GO; GO:0034595; F:phosphatidylinositol phosphate 5-phosphatase activity; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0052629; F:phosphatidylinositol-3,5-bisphosphate 3-phosphatase activity; TAS:Reactome.
DR   GO; GO:0043813; F:phosphatidylinositol-3,5-bisphosphate 5-phosphatase activity; TAS:Reactome.
DR   GO; GO:0004438; F:phosphatidylinositol-3-phosphatase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0004439; F:phosphatidylinositol-4,5-bisphosphate 5-phosphatase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0043812; F:phosphatidylinositol-4-phosphate phosphatase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0046855; P:inositol phosphate dephosphorylation; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0007612; P:learning; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0006836; P:neurotransmitter transport; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046856; P:phosphatidylinositol dephosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0046488; P:phosphatidylinositol metabolic process; ISS:ParkinsonsUK-UCL.
DR   GO; GO:1904980; P:positive regulation of endosome organization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0048488; P:synaptic vesicle endocytosis; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0016082; P:synaptic vesicle priming; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0048489; P:synaptic vesicle transport; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0016191; P:synaptic vesicle uncoating; ISS:ParkinsonsUK-UCL.
DR   Gene3D; 3.60.10.10; -; 1.
DR   InterPro; IPR015047; DUF1866.
DR   InterPro; IPR005135; Endo/exonuclease/phosphatase.
DR   InterPro; IPR000300; IPPc.
DR   InterPro; IPR000504; RRM_dom.
DR   InterPro; IPR002013; SAC_dom.
DR   Pfam; PF08952; DUF1866; 1.
DR   Pfam; PF03372; Exo_endo_phos; 1.
DR   Pfam; PF02383; Syja_N; 1.
DR   SMART; SM01165; DUF1866; 1.
DR   SMART; SM00128; IPPc; 1.
DR   SUPFAM; SSF54928; SSF54928; 1.
DR   SUPFAM; SSF56219; SSF56219; 2.
DR   PROSITE; PS50102; RRM; 1.
DR   PROSITE; PS50275; SAC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Disease mutation; Endocytosis; Hydrolase; Methylation;
KW   Neurodegeneration; Parkinson disease; Parkinsonism; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; RNA-binding.
FT   CHAIN         1   1573       Synaptojanin-1.
FT                                /FTId=PRO_0000209730.
FT   DOMAIN      119    442       SAC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00183}.
FT   DOMAIN      902    971       RRM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00176}.
FT   REPEAT     1396   1398       1.
FT   REPEAT     1406   1408       2.
FT   REPEAT     1417   1419       3.
FT   REGION      500    899       Catalytic. {ECO:0000255}.
FT   REGION     1396   1419       3 X 3 AA repeats of N-P-F.
FT   COMPBIAS    900   1573       Pro-rich.
FT   COMPBIAS   1033   1036       Poly-Ser.
FT   COMPBIAS   1108   1113       Poly-Pro.
FT   COMPBIAS   1126   1129       Poly-Pro.
FT   COMPBIAS   1485   1488       Poly-Glu.
FT   COMPBIAS   1538   1544       Poly-Pro.
FT   MOD_RES     820    820       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8CHC4}.
FT   MOD_RES     830    830       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1053   1053       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62910}.
FT   MOD_RES    1150   1150       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8CHC4}.
FT   MOD_RES    1178   1178       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62910}.
FT   MOD_RES    1201   1201       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:Q8CHC4}.
FT   MOD_RES    1220   1220       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1292   1292       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1318   1318       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1345   1345       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1349   1349       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q8CHC4}.
FT   MOD_RES    1551   1551       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1565   1565       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     451    451       K -> KAGK (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_035709.
FT   VAR_SEQ     504    511       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_035710.
FT   VAR_SEQ     525   1573       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_035711.
FT   VAR_SEQ    1144   1159       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:10048485}.
FT                                /FTId=VSP_041578.
FT   VAR_SEQ    1306   1311       VKTNGI -> QEQPSG (in isoform 2 and
FT                                isoform 3). {ECO:0000303|PubMed:10048485,
FT                                ECO:0000303|PubMed:9428629}.
FT                                /FTId=VSP_002682.
FT   VAR_SEQ    1312   1573       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:10048485,
FT                                ECO:0000303|PubMed:9428629}.
FT                                /FTId=VSP_002683.
FT   VARIANT     219    219       R -> Q (in PARK20; impairs the
FT                                phosphatase activity of the enzyme toward
FT                                phosphatidylinositol-3-phosphate and
FT                                phosphatidylinositol-4-phosphate).
FT                                {ECO:0000269|PubMed:23804563,
FT                                ECO:0000269|PubMed:23804577}.
FT                                /FTId=VAR_070905.
FT   VARIANT     295    295       K -> R (in dbSNP:rs2254562).
FT                                {ECO:0000269|PubMed:9428629}.
FT                                /FTId=VAR_047308.
FT   VARIANT    1366   1366       V -> A (in dbSNP:rs9980589).
FT                                /FTId=VAR_047309.
FT   VARIANT    1383   1383       S -> R (in PARK20; unknown pathological
FT                                significance; the patient also carries a
FT                                heterozygous PINK1 truncating mutation).
FT                                {ECO:0000269|PubMed:23804577}.
FT                                /FTId=VAR_070906.
FT   VARIANT    1508   1508       P -> L (in dbSNP:rs2230767).
FT                                /FTId=VAR_059357.
FT   VARIANT    1545   1545       L -> P (in dbSNP:rs2230767).
FT                                /FTId=VAR_047310.
FT   VARIANT    1547   1547       P -> L (in dbSNP:rs2230767).
FT                                /FTId=VAR_049603.
FT   CONFLICT   1093   1108       Missing (in Ref. 1; BAA74933).
FT                                {ECO:0000305}.
FT   CONFLICT   1366   1366       V -> VNT (in Ref. 1; AAC51922).
FT                                {ECO:0000305}.
FT   STRAND      895    901       {ECO:0000244|PDB:2DNR}.
FT   TURN        905    907       {ECO:0000244|PDB:2DNR}.
FT   HELIX       912    923       {ECO:0000244|PDB:2DNR}.
FT   STRAND      928    933       {ECO:0000244|PDB:2DNR}.
FT   STRAND      935    944       {ECO:0000244|PDB:2DNR}.
FT   HELIX       945    950       {ECO:0000244|PDB:2DNR}.
FT   HELIX       951    954       {ECO:0000244|PDB:2DNR}.
FT   STRAND      962    968       {ECO:0000244|PDB:2DNR}.
SQ   SEQUENCE   1573 AA;  173103 MW;  D50B249B1EBFFC18 CRC64;
     MAFSKGFRIY HKLDPPPFSL IVETRHKEEC LMFESGAVAV LSSAEKEAIK GTYSKVLDAY
     GLLGVLRLNL GDTMLHYLVL VTGCMSVGKI QESEVFRVTS TEFISLRIDS SDEDRISEVR
     KVLNSGNFYF AWSASGISLD LSLNAHRSMQ EQTTDNRFFW NQSLHLHLKH YGVNCDDWLL
     RLMCGGVEIR TIYAAHKQAK ACLISRLSCE RAGTRFNVRG TNDDGHVANF VETEQVVYLD
     DSVSSFIQIR GSVPLFWEQP GLQVGSHRVR MSRGFEANAP AFDRHFRTLK NLYGKQIIVN
     LLGSKEGEHM LSKAFQSHLK ASEHAADIQM VNFDYHQMVK GGKAEKLHSV LKPQVQKFLD
     YGFFYFNGSE VQRCQSGTVR TNCLDCLDRT NSVQAFLGLE MLAKQLEALG LAEKPQLVTR
     FQEVFRSMWS VNGDSISKIY AGTGALEGKA KLKDGARSVT RTIQNNFFDS SKQEAIDVLL
     LGNTLNSDLA DKARALLTTG SLRVSEQTLQ SASSKVLKSM CENFYKYSKP KKIRVCVGTW
     NVNGGKQFRS IAFKNQTLTD WLLDAPKLAG IQEFQDKRSK PTDIFAIGFE EMVELNAGNI
     VSASTTNQKL WAVELQKTIS RDNKYVLLAS EQLVGVCLFV FIRPQHAPFI RDVAVDTVKT
     GMGGATGNKG AVAIRMLFHT TSLCFVCSHF AAGQSQVKER NEDFIEIARK LSFPMGRMLF
     SHDYVFWCGD FNYRIDLPNE EVKELIRQQN WDSLIAGDQL INQKNAGQVF RGFLEGKVTF
     APTYKYDLFS DDYDTSEKCR TPAWTDRVLW RRRKWPFDRS AEDLDLLNAS FQDESKILYT
     WTPGTLLHYG RAELKTSDHR PVVALIDIDI FEVEAEERQN IYKEVIAVQG PPDGTVLVSI
     KSSLPENNFF DDALIDELLQ QFASFGEVIL IRFVEDKMWV TFLEGSSALN VLSLNGKELL
     NRTITIALKS PDWIKNLEEE MSLEKISIAL PSSTSSTLLG EDAEVAADFD MEGDVDDYSA
     EVEELLPQHL QPSSSSGLGT SPSSSPRTSP CQSPTISEGP VPSLPIRPSR APSRTPGPPS
     AQSSPIDAQP ATPLPQKDPA QPLEPKRPPP PRPVAPPTRP APPQRPPPPS GARSPAPTRK
     EFGGIGAPPS PGVARREMEA PKSPGTTRKD NIGRSQPSPQ AGLAGPGPAG YSTARPTIPP
     RAGVISAPQS HARASAGRLT PESQSKTSET SKGSTFLPEP LKPQAAFPPQ SSLPPPAQRL
     QEPLVPVAAP MPQSGPQPNL ETPPQPPPRS RSSHSLPSEA SSQPQVKTNG ISDGKRESPL
     KIDPFEDLSF NLLAVSKAQL SVQTSPVPTP DPKRLIQLPS ATQSNVLSSV SCMPTMPPIP
     ARSQSQENMR SSPNPFITGL TRTNPFSDRT AAPGNPFRAK SEESEATSWF SKEEPVTISP
     FPSLQPLGHN KSRASSSLDG FKDSFDLQGQ STLKISNPKG WVTFEEEEDF GVKGKSKSAC
     SDLLGNQPSS FSGSNLTLND DWNKGTNVSF CVLPSRRPPP PPVPLLPPGT SPPVDPFTTL
     ASKASPTLDF TER
//
